The acquisition has closed, MASI shareholders have been cashed out at $180/share. Any remaining shares should be tendered for the merger consideration. Monitor Danaher (DHR) for integration updates and potential synergies in the medical technology segment.
How the stock moved after the report
BULLISH VIEWSTOCK AT ENTRY AT T+5- T+0 · Jun 10 $179.95entry
- T+1 · 5mo ago 0.00%α −1.70% · $179.95
- T+5 · 5mo ago 0.00%α −2.14% · $179.95
- T+20 · due 4mo ago Pending
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Danaher Corporation has completed its acquisition of Masimo Corp on June 10, 2026, with Masimo shareholders receiving $180.00 per share in cash, representing a 38% premium to the pre-announcement price. Masimo's common stock ceased trading on Nasdaq and will be deregistered, with the company becoming a wholly owned subsidiary of Danaher. The Merger Agreement's credit facility was terminated and repaid, the board was replaced, and three executives (Catherine Szyman, Gregory Meehan, Charles Dadswell) entered into separation and consulting agreements for a three-month transition period.
Key Facts
- Danaher completed the acquisition of Masimo Corp on June 10, 2026, with Masimo becoming a wholly owned subsidiary of Danaher.
- Masimo shareholders received $180.00 per share in cash, a 38% premium to the pre-announcement stock price.
- Masimo's common stock ceased trading on Nasdaq prior to the market open on the Closing Date and will be deregistered via Form 25 and Form 15.
- Six directors resigned from the Masimo board at the Effective Time; Frank McFaden (director of Merger Sub) became the sole director of the surviving corporation.
- The company terminated and repaid all obligations under its Credit Agreement with Bank of America dated December 1, 2025.
- Catherine Szyman, Gregory Meehan, and Charles Dadswell entered into separation and consulting agreements with a 3-month consulting period post-closing.
- Parent funded the acquisition with cash on hand.
Financial Impact
Danaher acquired Masimo for approximately $9.4 billion, paying $180.00 per share in cash. The premium to pre-announcement price was approx. 38%.
Risk Factors
- Integration risk: combining Masimo's operations with Danaher's existing life sciences portfolio could face execution challenges.
- Regulatory risk: potential antitrust or regulatory conditions attached to the merger could impose operational constraints.
- Key personnel risk: three senior executives (Catherine Szyman, Gregory Meehan, Charles Dadswell) have departed, with only a 3-month consulting transition period.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-072151 |
| Document: tm2617395d1_ex3-2.htm | 0001104659-26-072151 |
| Document: tm2617395d1_8k.htm | 0001104659-26-072151 |
| Document: tm2617395d1_ex3-1.htm | 0001104659-26-072151 |
| Document: 0001104659-26-072151-index-headers.html | 0001104659-26-072151 |
| Document: 0001104659-26-072151-index.html | 0001104659-26-072151 |
| Document: 0001104659-26-072151.txt | 0001104659-26-072151 |
Track record
10 reports on MASI
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +1.94% at T+60 after the Feb 27, 2026 report. 4 of 4 went positive at some point.
Filters
- Oct 12, 20265w ago Institutional Cluster Bearish 4/10 No price data
- Jun 22, 202621w ago 15-12G Neutral 4/10 No price data
- Jun 10, 202622w ago 8-K Bullish 8/10 Viewing Entry $179.95 No price data
- May 4, 202628w ago 8-K Bullish 8/10 Entry $177.90 to $178.59 ▲ +0.39% −5.26% vs SPY
- Apr 21, 202629w ago Court Ruling Bearish 6/10 Entry $178.21 to $178.80 ▼ −0.33% +4.59% vs SPY
- Apr 1, 202632w ago DEFM14A Bullish 8/10 Entry $177.95 to $178.46 ▲ +0.28% −9.44% vs SPY
- Mar 18, 202634w ago PREM14A Neutral 4/10 Entry $178.51 to $177.96 ▼ −0.31% −7.93% vs SPY
- Feb 27, 202637w ago DFAN14A Bullish 9/10 Entry $175.27 to $177.00 ▲ +0.99% +8.93% vs SPY
- Jan 23, 202642w ago Court Ruling Neutral 2/10 Entry $142.48 No price data
- Jan 23, 202642w ago Court Ruling Neutral 2/10 Entry $142.48 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers